About this Research Topic
Over the past several years, unremitting efforts have been made in the Carbonic Anhydrase field to expand the knowledge on their biochemical, structural, and functional roles. The design and development of new molecules to be used as drugs has been constantly undertaken. Multidisciplinary approaches have been carried out in order to improve research and several engineering approaches have been developed to deeper the knowledge in the field.
Here we will present the latest issues regarding Carbonic Anhydrases, covering the most recent discoveries of basic research from health to environmental and biotechnological science, offering new perspectives for innovative applications of these fundamental enzymes, and new developments that can be gained from current investigations.
Researchers are invited to submit to this Research Topic original research and review articles focusing on:
• Advances in new developed inhibitors and activators of CAs
• Employment of hCAs as pharmacological and diagnostic targets
• Application of CAs in biotechnology
• Regulation of hCAs expression and their physiological consequences
• Roles of CAs in human diseases
• CAs in plants, bacteria, corals and other organisms
Dr. Supuran is an inventor of the patent WO2012/021963 which claims a carbonic anhydrase inhibitor (SLC-0111) now in clinical development. All other Topic Editors declare no competing interests.
Keywords: Carbonic anhydrase, inhibitors, drug design, biotechnological application, human disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.